Seegene, a global total solution provider for molecular diagnostics, announced that its U.S. subsidiary Seegene USA has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Allplex™ HSV-1&2/VZV/MPXV Assay (Allplex).


Allplex is a real-time syndromic PCR diagnostic product designed to simultaneously detect multiple viral pathogens that cause skin and mucosal lesions with similar clinical presentations. Previously, there were products that individually detected herpes simplex virus (HSV-1 and HSV-2), varicella-zoster virus (VZV), and mpox virus (MPXV). However, there were no products capable of testing for these viruses with similar symptoms in a single assay. As a result, there was a need for an integrated diagnostic solution that could quickly identify the cause of infection and increase diagnostic accuracy. The Allplex™ HSV-1&2/VZV/MPXV Assay, which can simultaneously detect HSV-1 and HSV-2, VZV, and MPXV, has obtained EUA from the FDA to address this need.

Seegene USA Syndromic PCR Diagnostic Product Receives FDA Emergency Use Authorization View original image

This product is designed to detect herpes simplex virus type 1 and 2 (HSV-1, HSV-2), varicella-zoster virus (VZV), and mpox (MPXV clades I/II and MPXV clade II) in a single test. This has been achieved through Seegene's proprietary syndromic PCR technology. Infections caused by these viruses often present with similar clinical symptoms, such as vesicular or pustular skin lesions, which are difficult to differentiate based solely on appearance. Therefore, if healthcare professionals perform testing targeting only a single pathogen, there is a possibility that infections caused by pathogens not included in the test may be missed in the diagnosis.


According to a study presented at the 2024 Clinical Virology Symposium, a reanalysis using multiplex PCR of specimens that tested negative in conventional single-pathogen tests revealed that 54 out of 966 cases contained previously undetected HSV, VZV, or MPXV clade I/II. This suggests that relying solely on single-target tests may miss certain infection cases.


Additionally, Allplex is the world’s first FDA EUA-approved product that can detect both clade I and II of the mpox virus and can identify clade II separately. This provides critical information for patient management and infection control.



Junbum Kim, President of Seegene USA, stated, “Seegene’s syndromic PCR technology is already widely used in markets around the world. This Emergency Use Authorization marks an important milestone in applying this technology more broadly in the U.S. market through Seegene USA, and it has laid the foundation for the development of syndromic molecular diagnostic products tailored to the needs of U.S. clinical laboratories and public health.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing